Investors Pile Into Amgen in Search of Next Obesity Drug Payout
- Share run-ups in Amgen have been short-lived, Mizuho says
- Detailed data on Amgen’s MariTide not expected until year-end
This article is for subscribers only.
Investors who may have missed out on the blistering rally in Eli Lilly & Co. and Novo Nordisk A/S are once again taking a chance with Amgen Inc.
The shares surged 12% Friday, the biggest one-day jump for Amgen in nearly 15 years, fueled by fresh optimism about the company’s future in the lucrative market for weight-loss drugs after upbeat commentary from the chief executive officer.